VIRACTA THERAPEUTICS, INC.

(VIRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index

12/16/2021 | 08:31am EDT

SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NBI is re-ranked each year and is calculated under a modified capitalization-weighted methodology. Additionally, the NBI forms the basis for a number of Exchange Traded Funds (ETFs). More information about the NBI, including eligibility criteria, can be found at https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy, Nana-Val, in a registration-enabling Phase 2 clinical trial for EBV-positive (EBV+) lymphoma and a Phase 1b/2 trial in patients with EBV+ nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com

Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)

 

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-be-added-to-the-nasdaq-biotechnology-index-301445981.html

SOURCE Viracta Therapeutics, Inc.


© PRNewswire 2021
All news about VIRACTA THERAPEUTICS, INC.
05/13Viracta Therapeutics Announces New Employment Inducement Grant
PR
05/11Viracta Therapeutics to Present at Upcoming May Investor Conferences
PR
05/10SUNESIS : Q1 Earnings Snapshot
AQ
05/10VIRACTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/10Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
PR
04/27VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/27TRANSCRIPT : Viracta Therapeutics, Inc. - Special Call
CI
04/20Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment o..
PR
04/15VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/15Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election A..
CI
More news
Analyst Recommendations on VIRACTA THERAPEUTICS, INC.
More recommendations